Anxiety Symptoms in Relation to Use of Hemp-derived, Full Spectrum Cannabidiol (CBD)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-06-01

Study Completion Date

2020-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Generalized anxiety disorder affects about 6.8 million adults in the United States, therefore its treatment is of major public health interest. Cannabidiol (CBD) has shown promise as an effective treatment for anxiety-related symptoms while lacking the severity of adverse effects seen with other medications. Given the wide availability of products containing CBD on the market today, from tinctures to coffee additives, and the undetermined potential for drug-to-drug interactions, medical supervision of CBD intake and formulation-specific clinical research is necessary. Therefore this study aimed to observe the effects of a specific hemp-derived full spectrum CBD formula on anxiety-related symptoms in a group of volunteers. The investigators will examine the self-reported anxiety symptoms in relation to use of a specific CBD formulation (25mg solvent-free full spectrum CBD capsules) in a cohort of adults diagnosed with generalized anxiety disorder. This open-label, cohort study will be conducted at six clinic sites in the United States (including Puerto Rico) from June 2020 through October 2020. The six physicians recruited to participate in the study were each actively prescribing CBD in their practices and were actively caring for patients with anxiety symptoms. Anxiety levels will be measured in enrolled participants diagnosed with generalized anxiety disorder each week for a period of eight weeks using the Generalized Anxiety Disorder 7-Item Scale (GAD7). Participants will also be instructed to take a daily 25mg capsule of CBD. The investigators hypothesize that this formula, when carefully developed and administered by a healthcare professional, will significantly reduce anxiety symptoms.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Use of CBD in the Treatment of Anxiety

NCT06672666

Anxiety Generalized Anxiety Disorder Sleep Problems

RECRUITING PHASE2

4 Week Veterans Cannabidiol Intervention

NCT05850754

Healthy

ACTIVE_NOT_RECRUITING NA

An Exploratory Investigation of a CBD Supplement's Impact on Sleep, Stress, and Focus

NCT05518019

Anxiety Fear Stress +2 more

COMPLETED NA

The Study of Hemp Oil CBD for Evaluation of Efficacy and Safety in Treatment of Pain, Anxiety and Insomnia Management

NCT04729244

CBD Pain, Chronic Anxiety +2 more

UNKNOWN PHASE1

Impact of CBD-Rich Oil on Aversive Memory Reconsolidation

NCT04726475

Anxiety and Fear

UNKNOWN PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Generalized Anxiety Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Formula30A Full Spectrum Hemp Cannabidiol 25mg Capsules

Formula30A Full Spectrum Hemp-Derived Cannabidiol (CBD) 25mg Capsules taken once daily for 8 weeks.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age between 21 and 85 years old.
* Research participants of both sexes.
* Good health conditions and without conditions that characterize them as belonging to the risk groups associated with adverse reactions to the product ingredients.
* Research participants with the potential to become pregnant may be included in the study as long as they are sexually abstinent or using a contraceptive method considered effective.
* Signature of the Free and Informed Consent Form.

Exclusion Criteria

* Initiation of or changes in use of medication or therapies in the past 2 weeks of start of study.
* Pregnancy or breastfeeding.
* History of hepatic compromise with transaminases of 2 times the upper limit of normal or cirrhosis.
* Diagnosis of Bi-Polar disorder, Schizophrenia or Suicidal Ideation.
* Current use of recreational marijuana, medical marijuana, or other CBD formulations.
* History of any substance or alcohol abuse.
* Current use of High Dose or Extended-Release Narcotics.
* Patients diagnosed with sleep apnea.

Minimum Eligible Age

21 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No